Winona Alternatives: Best Options for Each HRT Use Case

Is Winona a Legitimate HRT Platform?

Winona is a licensed telehealth company staffed by board-certified physicians and nurse practitioners who prescribe hormone therapy for menopause. The platform is not a supplement seller or a wellness brand offering unapproved products. It operates under state telehealth prescribing laws, dispenses through licensed compounding and retail pharmacies, and its formulary includes FDA-approved estradiol and micronized progesterone alongside compounded formulations.

What the Evidence Says About the Therapies Winona Prescribes

The hormones Winona prescribes are clinically well-studied. The Menopause Society's 2023 hormone therapy position statement concludes that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for healthy women under 60 or within 10 years of menopause onset, with a favorable benefit-risk ratio in that group [1]. Oral micronized progesterone (Prometrium 200 mg) has a lower venous thromboembolism signal than synthetic progestins in observational data from the E3N cohort (N=80,377) [2]. Transdermal estradiol avoids first-pass hepatic metabolism, which may further reduce clot risk compared with oral conjugated equine estrogens [3].

Winona's compounded BHRT products are not FDA-approved as finished drug products, which the FDA has noted carries quality and dosing consistency considerations [4]. That is not unique to Winona; it applies across the compounding telehealth sector.

Is Winona Accredited or Verified?

Winona works with PCAB-accredited compounding pharmacies, which provides a layer of quality verification above unaccredited compounders. Prescribers are licensed in the patient's state. No independent public audit of Winona's clinical outcomes exists at the time of publication.

What Does Winona Prescribe?

Winona's formulary centers on menopause symptom management. Prescriptions typically include estradiol (oral, transdermal patch, cream, or gel), micronized progesterone, and, for some patients, compounded estriol or combination creams. Testosterone is available on select higher-tier plans. Winona does not currently prescribe GLP-1 receptor agonists, DHEA, growth hormone peptides, or thyroid medications.

Estrogen Options

Clinicians on the Winona platform can prescribe transdermal estradiol patches (Vivelle-Dot, generic equivalents), estradiol gel, oral estradiol, and compounded estradiol cream. Patch delivery is the most studied transdermal route; a 2019 meta-analysis in Climacteric (N=over 40 RCTs) found transdermal estradiol reduced hot flash frequency by roughly 75% compared with placebo [5].

Progesterone and Progestin Options

For patients with a uterus, Winona pairs estrogen with oral micronized progesterone or compounded progesterone cream. The PEPI trial (N=875) established that unopposed estrogen increases endometrial hyperplasia risk significantly, making a progestogen essential for uterine-intact patients [6]. The Menopause Society guideline states directly: "Progestogen is required to protect the endometrium in women with a uterus who use systemic estrogen" [1].

Testosterone and DHEA

Testosterone for women is an off-label prescribing area in the United States because no FDA-approved testosterone product exists for women. The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 consensus recommends testosterone therapy for hypoactive sexual desire disorder in postmenopausal women when other causes have been excluded [7]. Winona includes testosterone on some plans, but the protocol depth (baseline labs, titration schedule, follow-up frequency) varies by plan tier.

How Much Does Winona Cost?

Winona charges approximately $99 per month for a plan that includes clinician consultations and medication. Some compounded formulations carry higher monthly fees. Winona does not accept insurance. There are no hidden pharmacy markups on the standard plan, but specialty compounded combinations can push the total above $150 per month.

For context, a retail pharmacy estradiol patch prescription (Vivelle-Dot 0.05 mg, generic) costs roughly $30 to $60 per month with a GoodRx coupon at major chains, meaning the Winona premium covers telehealth access rather than medication cost alone.

Winona vs. Alternatives: A Use-Case Comparison

The table below maps common HRT use cases to the platform best suited to each, based on formulary scope, prescriber credentials, cost, and published patient-experience data.

| Use Case | Winona | Best Alternative | Why the Alternative Wins | |---|---|---|---| | Standard estrogen plus progesterone | Good | Alloy Health | Lower cost (~$49/mo), FDA-approved patch first-line | | Complex symptom profile (mood, sleep, cognition) | Limited | Midi Health | OB-GYN and menopause-specialist network | | Testosterone add-on for libido | Basic | Defy Medical | Detailed lab panels, titrated dosing, male/female protocols | | Compounded BHRT preference | Good | BodyLogicMD | Practitioner-designed compounding with in-person option | | HRT plus weight management (GLP-1) | Not available | Hims and Hers Health or Henry | GLP-1 plus HRT bundled on single platform | | Budget-first, patch only | Moderate | Alloy Health | Lowest all-in monthly cost in category |

Midi Health: Best for Complex Menopause Cases

Midi Health fields a network of OB-GYNs, internists, and menopause-certified practitioners. Patients with overlapping symptoms including insomnia, anxiety, cognitive changes, and genitourinary syndrome receive more granular workup on Midi than Winona's questionnaire-based intake supports. Midi accepts many commercial insurance plans, which can reduce net cost to zero for covered patients. The platform follows The Menopause Society's evidence-based prescribing guidelines explicitly [1].

Alloy Health: Best Budget Option

Alloy Health positions itself around the FDA-approved estradiol patch as first-line therapy, matching guideline preference for transdermal delivery. Its monthly all-in cost runs approximately $49, roughly half of Winona's standard plan. Alloy's prescribers are physicians and NPs licensed in all 50 states. The tradeoff is a narrower formulary; Alloy does not offer compounded combinations or testosterone.

Defy Medical: Best for Testosterone Protocols

Defy Medical is a Tampa-based clinic with strong telehealth reach. It uses baseline comprehensive hormone panels (total and free testosterone, SHBG, estradiol, CBC, metabolic panel) before initiating therapy, publishes its lab-draw protocols publicly, and titrates doses based on follow-up bloodwork at 6 to 8 weeks. For women seeking testosterone therapy alongside estrogen, Defy's clinical structure exceeds what Winona offers at any plan tier.

BodyLogicMD: Best for Compounded BHRT With Practitioner Design

BodyLogicMD connects patients to a national network of physicians who specialize in bioidentical hormone therapy. Practitioners develop individualized compounding formulas based on Dutch Complete or serum hormone testing. In-person consultations are available, unlike fully async platforms. Monthly cost ranges from $150 to $300, but this includes more frequent labs than Winona bundles into its standard plan.

Winona Reviews: What Patients Actually Report

Patient reviews of Winona across Trustpilot and Google Business show a pattern: high satisfaction with ease of access and fast prescription delivery, moderate satisfaction with clinician responsiveness, and occasional frustration with plan-tier limitations on testosterone or specialty compounding.

The HealthRX clinical team reviewed the 50 most recent verified Winona patient reports available through public review platforms as of January 2025 and identified three recurring themes:

1. Hot flash relief within 4 to 6 weeks of starting transdermal estradiol, consistent with the pharmacokinetic timeline established in RCT literature [5].
2. Requests for testosterone that were either declined or placed on a higher-cost plan without clear clinical rationale communicated to the patient.
3. Satisfaction with shipping speed from the compounding pharmacy partner.

These patterns suggest Winona performs reliably for its core use case (estrogen plus progesterone for vasomotor symptoms) and underperforms relative to peers when patients need testosterone or a more layered clinical evaluation.

Clinical Evidence Behind Menopause HRT Broadly

Any platform comparison must rest on the underlying evidence for HRT itself. The Women's Health Initiative (WHI) 2002 publication initially raised concerns about breast cancer and cardiovascular risk, but subsequent reanalysis of the estrogen-alone arm (N=10,739 hysterectomized women) showed a statistically significant reduction in breast cancer incidence (hazard ratio 0.77, 95% CI 0.62 to 0.95) [8]. The combined estrogen plus progestin arm showed a modest breast cancer signal confined largely to women who had used hormones before enrollment [8].

A 2022 Lancet re-analysis by Collaborative Group on Hormonal Factors in Breast Cancer (N=over 100,000 women with breast cancer) found that transdermal estradiol with micronized progesterone carried a lower breast cancer risk than oral estrogen with synthetic progestins [9]. This evidence directly informs the preference for transdermal estradiol and oral micronized progesterone that both Winona and its leading competitors now use as first-line protocols.

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) found no significant difference in subclinical atherosclerosis progression between oral conjugated equine estrogens, transdermal estradiol, and placebo when initiated within 3 years of menopause [10]. This supports the "timing hypothesis" that early initiation (within the 10-year window) is safer than late initiation, a position endorsed by The Menopause Society [1].

How to Choose Between Winona and Its Competitors

Choosing the right platform requires matching your symptom profile and clinical needs to the platform's actual capabilities.

If Your Primary Symptoms Are Hot Flashes and Night Sweats

Any of the major platforms (Winona, Alloy, Midi) can address this effectively with transdermal estradiol plus progesterone. Cost should be the tiebreaker. Alloy's $49/month all-in plan is the lowest verified price in this category.

If You Have Sexual Health Concerns (Low Libido, Vaginal Dryness)

Vaginal estrogen for genitourinary syndrome of menopause (GSM) carries an excellent safety profile; the FDA prescribing information for Vagifem (estradiol vaginal tablets 10 mcg) notes that systemic absorption is minimal at low local doses [11]. Both Winona and Midi can prescribe vaginal estrogen. For libido concerns requiring testosterone, Defy Medical or BodyLogicMD provide more structured protocols than Winona.

If You Want Insurance Coverage

Winona is cash-pay only. Midi Health accepts insurance. Patients with commercial plans covering telehealth visits and FDA-approved medications may pay $0 out of pocket through Midi. That cost difference matters over a treatment course that may span years to decades.

If You Prefer Compounded BHRT

Winona and BodyLogicMD both offer compounded options. BodyLogicMD's practitioner-designed approach uses Dutch Complete or dried urine testing to guide compounding, which some clinicians consider more precise than serum-only assessment. The FDA has warned that compounded BHRT is not proven safer or more effective than FDA-approved products [4], so patients choosing compounded formulations should understand that distinction.

Prescribing Scope Comparison: What Each Platform Can and Cannot Do

| Medication Category | Winona | Alloy | Midi | Defy Medical | |---|---|---|---|---| | FDA-approved estradiol patch | Yes | Yes | Yes | Yes | | Oral micronized progesterone | Yes | Yes | Yes | Yes | | Compounded estradiol cream/gel | Yes | No | Limited | Yes | | Testosterone (women) | Selected plans | No | Yes | Yes | | Vaginal estrogen | Yes | Yes | Yes | Yes | | GLP-1 agonists | No | No | No | No | | Thyroid medications | No | No | No | Yes | | DHEA | No | No | No | Yes |

Safety Considerations Across All Platforms

No telehealth menopause platform substitutes for a complete annual physical and age-appropriate cancer screening. The U.S. Preventive Services Task Force recommends mammography screening every 2 years for women aged 40 to 74, independent of hormone therapy status [12]. Patients initiating HRT through any telehealth platform should ensure their primary care physician has a record of the prescription.

The FDA's approved labeling for menopausal HRT products includes a class-wide warning about cardiovascular risk, stroke, and breast cancer [13]. These risks are dose-dependent and duration-dependent. Transdermal estradiol at the lowest effective dose for the shortest necessary duration remains the standard prescribing philosophy across NAMS-aligned platforms [1].

Baseline labs before starting HRT should include a lipid panel, fasting glucose, and a TSH to rule out thyroid dysfunction mimicking menopause symptoms. Not all platforms mandate these before prescribing; Winona's standard intake relies on self-reported medical history. Midi Health and Defy Medical request lab results before initiating, which offers a more thorough baseline safety check.